Voyagen

Voyagen is a pharmatech startup pioneering the discovery of transcription factors as next-generation targets for oncology, with a focus on gastrointestinal tumors where current therapies are ineffective. Once considered undruggable, transcription factors have recently emerged as viable therapeutic targets, opening a new frontier for cancer treatment. Now it is time to step in and uncover their key role in disease. To achieve this, we need to dive into the dark genome, a largely unexplored space that is controlled by transcription factors. Technological limitations kept the dark genome hidden thus far, leaving many key drivers of cancer undiscovered. Using Voyagen’s IP-protected proprietary platform, TFprofiler and Dark Genome AI Engine, Voyagen is mapping this underexplored space, revealing disease-driving transcription factors and unlocking a new class of high-impact, druggable targets.

Voyagen was founded by a unique multidisciplinary team: Max Trauernicht, Lucía Barbadilla Martínez, and Minh Chau Luong Boi, bringing together deep expertise in systems biology, clinical AI, and precision oncology. Our long-term ambition is to become a drug discovery company that develops first-in-class therapies targeting transcription factors in gastrointestinal cancer. Beyond oncology, our platform’s capabilities extend to partner-driven target discovery in other therapeutic areas, broadening both our impact and commercial potential.